ArticleCancer immunology, immunotherapy : CII2008
The neoplastically transformed (CD30hi) Marek's disease lymphoma cell phenotype most closely resembles T-regulatory cells.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- The immune system of chicken and its response to H9N2 avian influenza virus.The veterinary quarterly · 2023Review
- The Importance of the Bursa of Fabricius, B Cells and T Cells for the Pathogenesis of Marek's Disease: A Review.Viruses · 2022Review
- Article
- Involvement of T Cell Immunity in Avian Coccidiosis.Frontiers in immunology · 2019Review
- Regulation of CD4Scientific reports · 2018Article
- Identification of the Receptor and Cellular Ortholog of the Marek's Disease Virus (MDV) CXC Chemokine.Frontiers in microbiology · 2017Article
- In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
- Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.BMC systems biology · 2012Article
- Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cells.Journal of virology · 2012Article
- GOModeler--a tool for hypothesis-testing of functional genomics datasets.BMC bioinformatics · 2010Article
- Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMarek's disease (MD), a herpesvirus-induced lymphoma of chickens is a unique natural model of CD30-overexpressing (CD30hi) lymphoma. We have previously proposed that the CD30hi neoplastically transformed CD4+ T cells in MD lymphomas have a phenotype antagonistic to cell mediated immunity. Here were test the hypothesis that the CD30hi neoplastically transformed MD lymphoma cells have a phenotype more closely resembling T-helper (Th)-2 or regulatory T (T-reg) cells. MATERIALS AND
methodsWe separated ex vivo-derived CD30hi, from the CD30lo/- (non-transformed), MD lymphoma cells and then quantified the relative amounts of mRNA and proteins for cytokines and other genes that define CD4+ Th-1, Th-2 or T-reg phenotypes. RESULTS AND DISCUSSION: Gene Ontology-based modeling of our data shows that the CD30hi MD lymphoma cells having a phenotype more similar to T-reg. Sequences that could be bound by the MD virus putative oncoprotein Meq in each of these genes' promoters suggests that the MD herpesvirus may play a direct role in maintaining this T-reg-like phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.